Menopausal Hot Flashes Market Trends, Value, Size, Share Opportunity and Market Forecast 2023-2030

Menopausal Hot Flashes Market is segmented By Product (Hormonal Products (Estrogen (Premarin, Vivelle, Vivelle-Dot), Progesterone (Prometrium), Combination Product (Prempro, Duavee)), Non-Hormonal Products (Brisdelle, Others)), By Distribution Channel (Online stores, Retail outlets, Others), By End-Users (Hospitals, Clinics, Academic & Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Menopausal Hot Flashes Market Overview

The Global Menopausal Hot Flashes Market is estimated to reach at a CAGR of 10.7% during the forecast period (2023-2030). Menopausal Hot Flashes are a medical condition that happens in women and is characterized by intense warmth over the whole body, which can be amid sweating and a red face and may last from 30 seconds to many minutes. Other symptoms include insomnia, dementia, and muscle mass loss. It's caused by the menopausal transition in women and is usually treated with hormone therapy, non-hormone therapy, or alternative methods like herbal drugs in conjunction with medication.

Menopausal Hot Flashes Market SUMMARY AND SCOPE

Menopausal Hot Flashes Market Dynamics and Trends

The increasing prevalence of menopausal hot flashes, the rising FDA approvals for drugs, and lifestyle changes like smoking, and alcohol consumption, are often triggering factors for menopausal hot flashes, contributing to the increase in the number of girls affected by the condition. 

Additionally, the healthcare sector and corporations have increased their awareness of Menopausal Hot Flashes in women regarding private hygiene through various channels like social media about its treatment. 

Rising Clinical Trials of Drugs for Treating Menopausal Hot Flashes are Expected to Drive Market Growth.

Astellas Pharma Global Development, Inc. has sponsored a Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women affected by Moderate to Severe Vasomotor Symptoms (Hot Flashes) and Considered Unsuitable for Hormone Replacement Therapy. Moreover, the study is estimated to be completed on May 30, 2023.

Furthermore, Bayer has sponsored a Phase 3 Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate the Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 52 Weeks in Postmenopausal Women. In addition, the study is estimated to be completed on March 29, 2023. Therefore, the increasing number of clinical trials of menopausal hot flashes drugs is expected to drive market growth in the forecast period.  

The Side Effects of Menopausal Hot Flashes Drugs are Expected to Hamper the Market Growth.

Clonidine (Catapres, Kapvay, others), a pill or patch typically used to treat high blood pressure, might provide some relief from hot flashes. Side effects can include dry mouth, eyes, constipation, nausea and dizziness. Thus, from the above factors, the market is expected to be hampered in the forecast period.

COVID-19 Impact on Menopausal Hot Flashes Market

The Coronavirus has moderately impacted the menopausal hot flashes market. According to gynecologist Barb DePree, MD, COVID-19 is unlikely to pose a significant additional risk to menopausal women. However, menopause is when women begin to have an increased risk for heart disease and type 2 diabetes due to the loss of estrogen's protective effects. These co-morbidities significantly increase the risk of COVID-19 infection in women. 

Furthermore, weight gain caused by menopause can complicate matters. As a result, numerous lifestyle changes can be made to protect a woman's body and keep her healthy, particularly during a pandemic when the patient must remain healthy. This begins with maintaining social distance and protecting herself by avoiding crowds, regularly washing hands and disinfecting the home.

Additionally, patients suffering from severe menopause hot flashes can contact a doctor through telemedicine. Besides, the drug clinical trials also got delayed, affecting the supply chain of pharmaceutical products. The restrictions on the production and export of medicines have affected many imported products, such as the United States and other countries. Thus, from the above factors, the market got affected, and it is expected to improve in the forecast period. 

Menopausal Hot Flashes Market Segmentation Analysis

The Hormonal Treatment Segment is Expected to Hold the Largest Market Share in the Menopausal Hot Flashes Market

The hormonal treatment segment accounted for the largest market share in 2021. Hormone therapy balances estrogen and progesterone levels in the body. It is an extremely effective treatment for hot flashes in women who can use it. They can also help with vaginal dryness, sleep, and bone density maintenance. Hormone therapy (also known as menopausal hormone therapy, or MHT) can be administered as pills, patches, rings, implants, gels or creams.

Furthermore, Estrogen medications work by increasing a woman's hormone levels and alleviating menopausal symptoms such as hot flashes. Some estradiol-containing medications approved by the USFDA to treat hot flashes include Alora, Estraderm, Estrogel, Evamist, Vivelle, Climara, Divigel and Estrace. 

According to several recent studies, non-estrogen medicines may have up to 70% of the efficacy of estrogen therapy in managing hot flashes. The estrogen segment dominates the market for menopausal hot flashes, and this trend is expected to continue throughout the forecast period. Estrogen replacement therapy has many advantages, including improved vaginal health, reduced menopausal symptoms, and the potential to improve bone and heart health. 

For instance, Vivelle-DOT (estradiol transdermal system) is a treatment for moderate to severe vasomotor symptoms associated with menopause and moderate to severe vulvar and vaginal atrophy. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Menopausal Hot Flashes Market Geographical Share

North America Region Holds the Largest Market Share in the Global Menopausal Hot Flashes Market  

North America region accounted for the largest market share in 2021. The increasing population of geriatric women with menopausal symptoms, the rising demand for treatments for hot flashes, increasing product launches and FDA approvals are the factors to drive the market in the forecast period. 

For instance, according to the North American Menopause Society, hot flashes affect approximately 75% of North American women during perimenopause. Almost a quarter of them are so bothered that they require medical attention. Menopause is common in older women, accelerating the market's overall growth rate.

Furthermore, TherapeuticsMD, Inc. submitted a supplemental New Drug Application ("NDA") to the US Food and Drug Administration in May 2021 for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg ("FDA"). BIJUVA is the only FDA-approved bio-identical hormone therapy pill containing estradiol and progesterone. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Menopausal Hot Flashes Companies and Competitive Landscape

Major key players in the menopausal hot flashes market are Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Agile Therapeutics, and Amgen Inc. 

On December 9, 2021, Acer Therapeutics Inc. was approved by the U.S. Food and Drug Administration (FDA) for the registration of Investigative New Drugs (IND) for the selective neurokinin 3 (NK3R) non-peptide receptor antagonist, ACER-801 (osanetant) for the potential treatment of Induced Vasomotor Symptoms (iVMS).

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and manufactures medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. Pfizer Limited has over 150 products across 15 therapeutic areas. It sells its vaccines to the federal government and the Centers for Disease Control and Prevention in the United States (CDC).

Product Portfolio:

DUAVEETM (conjugated estrogens/bazedoxifene): DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.

The Global Menopausal Hot Flashes Market Report Would Provide Access to Approx. 45+ Market Data Tables, 40+ Figures and 180 Pages.